3RD ROCK MULTIMEDIA LTD Q3 RESULTS
TCS Q1 results; Pine Labs, Swiggy valuations slashed
Indian IT bellwether TCS kicked off the tech earnings season with a 9% YoY growth in net profit for the June quarter. This and more on today's ETtech Top 5.
Hold your horses! Wait for real results before making big moves: Swaminathan Aiyar
In Modi 1, he, for instance tried to take on land acquisition. He retreated. Again, in Modi 2, one of the things that he retreated on perhaps was whether we have a national register of citizens, which the Muslim community is extremely afraid of, that is a non-economic subject. But I mean, these were some of the areas Mr Modi has shown that he is capable of retreating when he comes across a very serious resistance.
Sun Pharma net profit jumps 34% YoY to Rs 2,654.6 crore in Q4FY24
Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.
Biocon Q4 Results: Net profit drops 57% to Rs 136 crore
Total revenue grew 1% YoY to Rs 3,966 crore. EBITDA for the quarter declined 16% YoY to Rs 964 crore, representing an EBITDA margin of 24% versus 29% in the same period last year. The gross R&D spends declined 36% YoY to Rs 228 crore in Q4FY24.
Cipla Q4 Results Preview: Profit may rise up to 71% YoY on healthy operations
Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarter surging by as much as 71% year-on-year, alongside an expected 7% year-on-year increase in net sales.
Dr Reddy’s shares tumble 5% as Q4 numbers fail to impress analysts. Should you buy, sell or hold?
Dr Reddy’s Share Price: The company said that the jump in YoY net profit was largely driven by growth in global generics revenues in North America as well as emerging markets. DRL’s revenue also increased 12% YoY to Rs 7,083 crore.
- Go To Page 1
IRB Infra shares rise over 4% after Q4 results. Should you buy or sell?
IRB Infrastructure Developers saw a 4.3% rise in shares on BSE as it reported a 45% YoY increase in Q4 net profit to Rs 188.9 crore, with revenue up 27% YoY.
Shares of M&M Finance dips 5% as NBFC postpones Q4 results on Rs 150 crore fraud detection
Mahindra & Mahindra Financial Services shares fell 5% to Rs 257 in early trading due to the announcement of delayed Q4 results following a fraud exceeding Rs 150 crore at a North East branch.
Shares of Jio Financial jumps 3% post Q4 results
Jio Financial Share Price: The reaction to the Q4 earnings can be seen today when the stock rose and hovered near its 52-week high of Rs 384.
Jio Financial Services shares slump 3% ahead of Q4 results today
Shares of Mukesh Ambani-led Jio Financial Services declined 3% at Rs 372 on BSE in Friday's early tarde as the investors await the fourth quarter earnings’ result later in the day.
Zydus Lifesciences net profit jumps 27% in Q3FY24, announced buyback
Zydus Lifesciences on Tuesday reported Rs 789.6 crore net profit in Q3FY24, a year-on-year (YoY) jump of 27% led by growth in India, Europe and emerging market formulation sales.
Biocon Q3 Results: PAT at Rs 660 crore vs Rs 42-crore loss a year ago
The company said the revenue growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' branded formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocon’s stake dilution in Bicara Therapeutics.
Lupin Q3 Results: Net profit triples to Rs 619 crore on sales growth
The company reported a net profit of Rs 158 crore in the corresponding quarter of the previous year. Revenue from operations grew 20.2% YoY to Rs 5197 crore in Q3FY24.
Torrent Pharma Q3 Results: Net profit jumps 52% YoY t Rs 443 crore
The company had reported a net profit of Rs 292 crore during the corresponding period of the previous year. Revenues rose 10% YoY to Rs 2,732 crore during Q3FY24, compared to Rs 2,491 crore in Q3FY23.
Sun Pharma Q3 Results: Net profit jumps 15.5% to Rs 2524 crore
Sun Pharma on Wednesday reported a 16.5% year-on-year (YoY) jump in net profit to Rs 2524 crore in Q3FY24 led by broad-based growth, including higher sales of global specialty products.
Sun Pharma Q3 results today: What to expect from India’s top drug maker?
Sun Pharma Q3 results: Sun Pharmaceutical Industries is set to release its Q3 results, with expected moderate earnings growth. Analysts will monitor factors including US business growth, Taro Pharmaceutical's performance, margin trajectory, planned product launches, and R&D investments. Estimated growth in net profit, revenue, and operating profit is also anticipated. The company is expected to see a rise in US revenue, driven by specialty sales. Growth in domestic formulations is projected, and R&D spend will be closely monitored.
Dr Reddy's shares rise 4% on Q3 PAT jump but brokerages remain unmoved. Here's why
The drug maker on Tuesday reported an 11% year-on-year (YoY) jump in net profit at Rs 1,379 crore for the quarter ended December 31, 2023, as against Rs 1,247 crore a year ago. The company said the net profit was led by new products and base business market share gain in the US, and also new launches and strong volumes in Europe. The Hyderabad-based firm's revenue rose 7% at Rs 7,215 crore as against Rs 6,770 crore crore in the year-ago period.
Q3 results today: Maruti, Sun Pharma, Dabur among 113 companies to announce earnings
Sun Pharmaceuticals and Maruti Suzuki India are among the companies declaring their Q3FY24 earnings. Maruti Suzuki India is expected to report healthy revenue growth, while Sun Pharmaceuticals may see moderate revenue growth.
Dr Reddy's Q3 Results: Net profit rises 11% YoY to Rs 1,379 crore, meets estimates
DRL Q3 Results: The profit was slightly above the ET Now poll estimate of Rs 1,337 crore. Revenue from operations increased 7% year-on-year (YoY) to Rs 7,215 crore. EBITDA for the reporting period stood at Rs 2,111 crore, while margins came in at 28%.
Sun Pharma Q3 preview: Consolidated PAT may rise 8% YoY amid moderate revenue growth
Sun Pharmaceutical Industries Ltd is expected to report single-digit revenue growth for Q3 earnings, with moderate sales in the US and India. Analysts predict a nearly 8% YoY growth in consolidated net profit to Rs 2,329 crore. Consolidated revenue is estimated to rise 9% YoY to Rs 12,265.40 crore.
Dr Reddy’s Q3 results today: What can Dalal Street expect from the drugmaker?
Dr Reddy’s Q3 results: Dr Reddy’s Laboratories is set to release its earnings for the December quarter later today. The company is expected to see a muted growth in revenue amid lower sales of generic anti-cancer drug Revlimid and moderate growth in India business. Higher raw material inflation is seen hurting the profitability. Analysts and investors will closely track management comments on outlook for the US, Russia, and India markets, planned product launches for FY25, and research and development spending of the company.
Cipla reports Rs 1049 crore net profit in Q3FY24, on strong US, India sales
Drug maker Cipla reported a 33% year-on-year (YoY) jump in net profit to Rs 1049 crore in Q3FY24, led by strong US and India sales momentum.
Cipla Q3 Results: Profit jumps 32% YoY to Rs 1,056 crore, revenue rises 14%
Cipla's Q3 revenue for the quarter grew 13.7% YoY to Rs 6,604 crore, compared to Rs 5,810 crore in the same quarter last year. However, the drugmaker saw a marginal decline from the previous quarter's revenue of Rs 6,678 crore. Meanwhile, its EBITDA surged 24.2% YoY to Rs 1,748 crore in the December quarter of FY24.
Asian Paints shares fall 6% post Q3 earnings. Should you buy, sell or hold?
Asian Paints shares dropped due to disappointing December quarter earnings. Kotak Institutional Equities recommended a 'Reduce' rating, Motilal Oswal reiterated a 'Neutral' view, while Nuvama remained upbeat with a buy recommendation. Asian Paints reported a 35% YoY rise in consolidated net profit for the quarter. Consolidated revenue from operations grew by 5.4% YoY.
Rs 1 lakh-crore loss! HDFC Bank shares record worst day since Covid crash
HDFC Bank, India's second most-valued stock, recorded its worst daily performance since the Covid crash 3 years ago, falling 8.5% and causing a market crash. Investors in the bluechip lost over Rs 1 lakh crore as the market capitalisation of the Nifty heavyweight fell to Rs 11.67 lakh crore. Several brokerages have reduced their target prices on the stock, contributing to the downfall.
After survival & revival, for next 3 years, it is ‘thrival’ for Federal Bank: Shyam Srinivasan
Shyan Srinivasan says: "We bring in about 20 odd percent of the India remittances that come into India. Initially, it was just the Middle East and Kerala. Now it is non-Middle East non-Kerala, Middle East non-Kerala all quadrants working in favour and we think we are getting a good traction on that. So, on balance, the bank is now as widespread, as prominent as we would like it to be across many geographies."
Jio Financial Services Q3 Results: Profit up on interest income, accounting gains
Reliance Industries' financial services arm Jio Financial Services said its profit increased eigtht times to Rs 70 crore in the quarter ended December 2023 from Rs 8 crore in the previous year due to higher interest income and due to gains on fair value changes.
Jio Financial results today: What will be the key watch outs for Dalal Street?
Jio Financial Q3 results: Reliance Industries' subsidiary Jio Financial Services will release its Q4 earnings for December. This is the second earnings announcement since listing. No estimates are available for the company's performance. For the six months ended September, Jio Financial reported a revenue of Rs 1,022 crore and a net profit of Rs 1,000 crore. The December quarter numbers will detail the performance of each business. Jio Financial Services plans to increase financial services penetration through a digital-first approach.
Q3 results today: Jio Financial, Angel One among 24 companies to announce earnings
Jio Financial Services, a subsidiary of Reliance Industries, will announce its Q3 earnings. The company, which became independent in August 2023, operates through six major subsidiaries including Jio Finance and Jio Insurance Broking. It is also awaiting approval from SEBI for a mutual fund business joint venture with BlackRock. Last quarter, Jio Financial reported a revenue of Rs 1,022 crore and a net profit of Rs 1,000 crore. The upcoming earnings will provide detailed performance of each business segment.
Load More
